Oncology| Volume 120, P173-179, October 2018

Comparative Effectiveness of Local and Systemic Therapy for T4 Prostate Cancer



      To evaluate the comparative effectiveness of local vs systemic therapy among patients diagnosed with nonmetastatic clinical T4 prostate cancer.


      Using the National Cancer Database men with clinical T4N0-1M0 prostate cancer from 2004 to 2013 were identified. Local therapy was defined as radiation (RT with androgen deprivation therapy [ADT]), surgery (radical prostatectomy with ADT), or combined radiation plus surgery (radical prostatectomy plus RT with ADT). Systemic therapy was defined as ADT or chemotherapy alone. The primary outcome of overall survival was estimated using the Kaplan-Meier method. Factors associated with overall survival were determined by Cox proportional hazards models.


      A total of 1914 patients were included in our analysis, 1559 received local therapy and 355 received systemic therapy. Median 5-year survival for local vs systemic therapy was 41.5 and 28.2 months, respectively. On multivariable analysis, local therapy was associated with increased overall survival compared to systemic therapy (hazard ratio [HR] = 0.52; 95% confidence interval [CI] 0.44-0.62, P < .001). Comparing local therapy treatment modalities, both radiation (HR = 0.44; 95% CI 0.36-0.53, P < .001) and surgery (HR = 0.67; 95% CI 0.55-0.82, P < .001) were associated with increased overall survival compared to systemic therapy. Among those receiving local therapy, more patients were treated with radiation (n = 709/1559 or 45.5%) compared to surgery (n = 560/1559 or 35.9%) or combined radiation plus surgery (n = 290/1559 or 18.6%) with 5-year overall survival by treatment type being 61%, 51.4%, and 62.2%, respectively.


      Local therapy for clinical T4 prostate cancer is associated with improved overall survival. Due to the retrospective, nonrandomized nature of the study design, a clinical trial is needed to better define the efficacy of local therapy in this high-risk patient population.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Moyer VA
        • U.S. Preventive Services Task Force
        Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
        Ann Intern Med. 2012; 157: 120-134
        • Huland H
        • Graefen M
        Changing trends in surgical management of prostate cancer: the end of overtreatment.
        Eur Urol. 2015; 68: 175-178
        • Silberstein JL
        • Vickers AJ
        • Power NE
        • et al.
        Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy.
        Cancer. 2011; 117: 4855-4860
        • Won AC
        • Gurney H
        • Marx G
        • De Souza P
        • Patel MI
        Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer.
        BJU Int. 2013; 112: E250-E255
        • Aus G
        • Hugosson J
        • Norlén L
        Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent.
        J Urol. 1995; 154 (PubMed PMID: 7541865): 466-469
        • Warde P
        • Mason M
        • Ding K
        • et al.
        NCIC CTG PR.3/MRC UKPR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
        Lancet. 2011; 378: 2104-2111
        • Widmark A
        • Klepp O
        • Solberg A
        • et al.
        Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
        Lancet. 2009; 373: 301-308
        • Bolla M
        • Collette L
        • Blank L
        • et al.
        Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.
        Lancet. 2002; 360: 103-106
        • NCCN Clinical Practice Guidelines in Oncology
        Prostate Cancer. 2014. 2015: 1-98
        • Rider JR
        • Sandin F
        • Andrén O
        • et al.
        Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
        Eur Urol. 2013; 63: 88-96
        • Johnstone PA
        • Ward KC
        • Goodman M
        • et al.
        Radical prostatectomy for clinical T4 prostate cancer.
        Cancer. 2006; 106: 2603-2609
        • Spahn M
        • Morlacco A
        • Boxler S
        • et al.
        European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPAcT). Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: a multi-institutional study of 62 patients.
        BJU Int. 2017; 120: E52-E58
        • Edge SB
        • Compton CC
        The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.
        Ann Surg Oncol. 2010; 17: 1471-1474
        • Zabell JR
        • Adejoro O
        • Jarosek SL
        • et al.
        Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis.
        World J Urol. 2016; 34: 1397-1403
        • Rusthoven CG
        • Carlson JA
        • Waxweiler TV
        • et al.
        The impact of definitive local therapy for lymphnode-positive prostate cancer: a population-based study.
        Int J Radiat Oncol Biol Phys. 2014; 88: 1064-1073
        • Boorjian SA
        • Thompson RH
        • Siddiqui S
        • et al.
        Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
        J Urol. 2007; 178: 864-870
        • Sooriakumaran P
        • Nyberg T
        • Akre O
        • et al.
        Survival among men at high risk of disseminated prostate cancer receiving initial locally directed radical treatment or initial androgen deprivation therapy.
        Eur Urol. 2017; 72: 345-351
        • Leibovici D
        • Kamat AM
        • Pettaway CA
        • et al.
        Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer.
        J Urol. 2005; 174: 2186-2190
        • Williams SB
        • Huo J
        • Chamie K
        • et al.
        Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: the limitations of cancer registry data.
        Cancer. 2017; 123: 1617-1624
        • Giordano SH
        • Kuo YF
        • Duan Z
        • et al.
        Limits of observational data in determining outcomes from cancer therapy.
        Cancer. 2008; 112: 2456-2466
        • Hsiao W
        • Moses KA
        • Goodman M
        • et al.
        Stage IV prostate cancer: survival differences in clinical T4, nodal and metastatic disease.
        J Urol. 2010; 184: 512-518
        • Boorjian SA
        • Karnes RJ
        • Viterbo R
        • et al.
        Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.
        Cancer. 2011; 117: 2883-2891
        • Berglund RK
        • Tangen CM
        • Powell IJ
        • et al.
        Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109.
        Urology. 2012; 79: 633-637
        • Matulay JT
        • DeCastro GJ
        Radical prostatectomy for high-risk localized or node-positive prostate cancer: removing the primary.
        Curr Urol Rep. 2017; 18: 53
        • Fossati N
        • Trinh QD
        • Sammon J
        • et al.
        Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study.
        Eur Urol. 2015; 67: 3-6
        • Culp SH
        • Schellhammer PF
        • Williams MB
        Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
        Eur Urol. 2014; 65: 1058-1066